ABPA Diagnosis: Tests and Criteria to Confirm It

Diagnosing allergic bronchopulmonary aspergillosis (ABPA) requires a combination of blood tests, imaging, and clinical judgment rather than any single definitive test. The condition arises when the immune system overreacts to the common mold Aspergillus fumigatus in the airways, and its symptoms overlap heavily with ordinary asthma, making it easy to miss. Because no one test confirms ABPA on its own, clinicians rely on a set of criteria that together build a convincing case, with total serum IgE and Aspergillus-specific antibodies forming the diagnostic backbone.

Who Gets ABPA and Why It Is Hard to Catch

ABPA almost exclusively affects people who already have asthma or cystic fibrosis. The fungus Aspergillus fumigatus is everywhere in the environment, and most people inhale its spores without consequence. In susceptible individuals, however, the spores persist in the airways and germinate, releasing proteins that trigger an intense allergic response dominated by a particular branch of the immune system.¹ That response produces a flood of IgE antibodies, an influx of eosinophils (a type of white blood cell tied to allergic reactions), and progressive airway damage if left untreated.

The challenge is that worsening wheeze, cough, and mucus production look identical to a badly controlled asthma flare or a lung infection. Genetic factors, including certain immune-system gene variants and mutations in the cystic fibrosis gene, predispose some people to the exaggerated allergic response that characterizes ABPA.² Without a high index of suspicion and the right tests, many cases go undiagnosed for years.

The Diagnostic Criteria and How They Have Evolved

The first formal diagnostic framework for ABPA was proposed by Rosenberg and colleagues in 1977, drawing on a series of 20 patients with asthma, lung infiltrates, and eosinophilia.³ That original set of criteria included asthma, a positive skin test to Aspergillus, elevated total IgE, Aspergillus-specific IgE and IgG antibodies, blood eosinophilia, pulmonary infiltrates on chest X-ray, and central bronchiectasis. The framework proved remarkably durable and remained the reference standard for decades.⁴

Over time, researchers recognized that not every patient checks every box, and that rigid adherence to all criteria at once can miss real cases. The International Society for Human and Animal Mycology (ISHAM) working group proposed updated criteria in 2013 and revised them again in 2024, reorganizing the diagnosis into obligatory prerequisites and additional supporting criteria.⁵ In the current ISHAM scheme, the two prerequisites are a predisposing condition (asthma or cystic fibrosis) and evidence of Aspergillus sensitization, typically shown by a positive skin prick test or elevated Aspergillus-specific IgE. Once those are met, clinicians look for additional criteria such as a markedly raised total IgE, elevated Aspergillus-specific IgG, blood eosinophilia, and consistent findings on chest imaging.

Total Serum IgE as the Central Screening Test

Total serum IgE is the single most important initial blood test for ABPA. In active disease, total IgE levels are dramatically elevated, often far beyond what you would see in typical allergic asthma. A study that specifically tried to find the best cutoff to separate ABPA from plain asthma identified a total IgE threshold of roughly 2,350 IU/mL, which achieved about 87% sensitivity and 81% specificity.⁶ In practice, many guidelines use a lower screening threshold (often around 1,000 IU/mL) to avoid missing cases, accepting that some false positives will need further workup.

Total IgE also has a second life after diagnosis: tracking treatment response. In a study of 81 patients, total IgE dropped by a median of about 52% after eight weeks of treatment. A rise of more than 50% over baseline later on reliably flagged a disease flare, catching over 90% of exacerbations.⁷ For this reason, clinicians typically establish a baseline total IgE at diagnosis and recheck it periodically. Aspergillus-specific IgE, by contrast, proved less useful for monitoring; in the same study, it actually rose in about half of treated patients despite clinical improvement.

Aspergillus-Specific IgE and IgG Antibodies

While total IgE casts a wide net, Aspergillus-specific antibodies help confirm that the immune reaction is directed at the right target. Specific IgE against A. fumigatus is present in both ABPA and simple Aspergillus allergy (sensitization without the full-blown disease), so its presence alone is not proof of ABPA. However, ABPA patients tend to have much higher levels. That same cutoff study found that a specific IgE threshold around 1.9 kUA/L separated ABPA from asthma with 99% sensitivity.⁶

Aspergillus-specific IgG adds another dimension. IgG antibodies against the fungus are elevated in both ABPA and a different condition called aspergilloma (a fungal ball in the lung), but they tend to be absent in simple Aspergillus asthma.⁸ A meta-analysis pooling data from multiple studies found that Aspergillus-specific IgG had about 93% sensitivity but only around 73% specificity for ABPA, meaning it catches most cases but produces a fair number of false positives. Specific IgE, meanwhile, showed about 83% sensitivity and 89% specificity.⁹ The two tests complement each other: IgG is better at ruling ABPA out (few false negatives), while IgE is better at ruling it in (fewer false positives).

Optimal IgG cutoffs may also depend on age. One study found that the best threshold for Aspergillus-specific IgG differed between patients younger and older than 55, suggesting that age-specific cutoffs could improve accuracy.¹⁰

Skin Prick Testing for Aspergillus Sensitization

An immediate skin prick test using A. fumigatus antigen extract is one of the quickest ways to demonstrate sensitization. A wheal-and-flare reaction within 15–20 minutes indicates IgE-mediated allergy to the fungus. In most diagnostic frameworks, a positive skin test (or an elevated Aspergillus-specific IgE in blood) satisfies the sensitization prerequisite for ABPA. The skin test is inexpensive and fast, but it only tells you the person’s immune system recognizes Aspergillus. It cannot distinguish simple sensitization from full ABPA, so it works as a screening gate rather than a standalone diagnosis.

What CT Scans Reveal

High-resolution computed tomography (HRCT) of the chest is the imaging modality of choice. Two findings are especially telling. Central bronchiectasis, meaning dilated airways in the inner two-thirds of the lung, has long been considered a hallmark of ABPA. In one study, 86 patients showed central bronchiectasis with a preference for the upper and middle lobes, along with centrilobular nodules in 86% and mucus plugging in 59%.¹¹

The second and arguably more distinctive finding is high-attenuation mucus (HAM), which are dense mucus plugs that appear brighter than surrounding muscle on CT. HAM is considered essentially diagnostic of ABPA when present. It shows up in roughly 20–36% of patients depending on the study, so its absence does not rule anything out, but its presence strongly points toward the diagnosis.¹² Peripheral bronchiectasis also occurs in a substantial proportion of ABPA cases, which has led some researchers to question whether “central” bronchiectasis should remain as strict a criterion as originally proposed.

The Limited Role of Eosinophil Counts

Blood eosinophilia is listed in most diagnostic frameworks, but its diagnostic value is modest. A dedicated study of eosinophil counts in ABPA patients concluded that peripheral eosinophil count has limited utility for diagnosis and does not correlate well with lung function or other immune markers.¹³ Higher eosinophil counts were, however, observed in patients who had central bronchiectasis or high-attenuation mucus, suggesting that eosinophils play a role in driving the inflammatory damage of ABPA even if counting them in blood is not a reliable diagnostic tool. Eosinophilia is common in many allergic conditions, so an elevated count supports the picture but should not be used to make or exclude the diagnosis on its own.

Sputum Culture and Molecular Detection

Growing Aspergillus from sputum might seem like the most direct proof that the fungus is involved, but cultures are surprisingly insensitive. In one study, fungal cultures were positive in only about 13% of sputum samples from ABPA and chronic pulmonary aspergillosis patients, with A. fumigatus accounting for most of the isolates.¹⁴ The fungus can be difficult to coax into growing in the lab, and a negative culture definitely does not rule out ABPA.

PCR-based molecular testing picks up Aspergillus DNA at higher rates. One study found PCR identified the fungus in 28% of sputum samples compared to 19% by culture, with high negative predictive value.¹⁵ PCR is useful when culture is negative but suspicion remains high. Still, neither culture nor PCR is part of the core diagnostic criteria for ABPA. They are adjuncts that can help confirm fungal presence when the serological picture is ambiguous.

Recombinant Antigen Testing for Better Precision

Aspergillus fumigatus produces dozens of allergenic proteins, but not all of them are equally relevant to ABPA. Researchers have developed tests using specific recombinant antigens, labeled rAsp f1 through f6, to sharpen the diagnosis. A meta-analysis found that IgE against a combination of rAsp f1 or f3 achieved about 97% sensitivity for diagnosing ABPA in asthmatics. Meanwhile, IgE against rAsp f4 or f6 showed the best specificity at over 99%.¹⁶ A separate study confirmed that IgE against rAsp f1 alone, at a defined cutoff, achieved 89% sensitivity and 100% specificity.¹⁷

The practical significance here is that these recombinant antigen tests can separate ABPA from simple Aspergillus sensitization with much more confidence than crude whole-fungus extracts. Antigens f4 and f6 are particularly valuable because they are rarely recognized by the immune system in merely sensitized asthmatics, so a positive result strongly suggests ABPA rather than ordinary fungal allergy. These tests are not yet universally available, but they are increasingly entering clinical practice and feature in the revised ISHAM guidelines.

Pulmonary Function Testing

Spirometry is part of the standard workup for anyone with asthma or suspected ABPA, though it is not diagnostic on its own. Interestingly, the most common pattern on lung function testing in ABPA is restrictive rather than purely obstructive. One study found a restrictive pattern in about 52% of patients and an obstructive pattern in about 40%.¹⁸ The restrictive component likely reflects mucus plugging and airway damage. Spirometry results can help gauge disease severity and track how lungs respond to treatment, but they do not distinguish ABPA from other causes of airflow limitation.

The Special Challenge of ABPA in Cystic Fibrosis

Diagnosing ABPA in someone with cystic fibrosis is harder than in asthma because the two conditions share so many features. Cystic fibrosis on its own causes mucus plugging, bronchiectasis, recurrent infections, and lung function decline, all of which also mark ABPA. The clinical and radiological features overlap to such a degree that ABPA remains underdiagnosed in this population.¹⁹

Current guidance for cystic fibrosis patients recommends suspecting ABPA when clinical and radiological deterioration cannot be explained by bacterial infection or other causes, particularly when total IgE is markedly elevated (while the patient is not on systemic steroids) and A. fumigatus sensitization is present. The recombinant antigen tests described above also perform well in cystic fibrosis, with IgE against rAsp f1 or f3 reaching about 93% sensitivity in CF patients.¹⁶

Distinguishing ABPA from Severe Asthma with Fungal Sensitization

One of the trickiest diagnostic boundaries is between ABPA and a condition called severe asthma with fungal sensitization (SAFS). SAFS sits on a continuum between ordinary Aspergillus-sensitized asthma and full ABPA, and it is defined essentially by exclusion: severe asthma plus fungal sensitization minus the criteria for ABPA.²⁰ In practice, the distinction matters because ABPA typically warrants systemic corticosteroids and sometimes antifungal therapy, while SAFS management focuses on asthma control and possibly antifungals alone.

The antibody levels can help draw the line. A study comparing the two groups found that ABPA patients had significantly higher Aspergillus-specific IgG and IgE than SAFS patients. Using a combined threshold of specific IgG above 1,000 U/mL and specific IgE above 1.0 kU/L achieved about 82% sensitivity and 79% specificity for differentiating ABPA from SAFS.²¹ This is decent but far from perfect, and clinicians sometimes have to make a judgment call based on the totality of the picture.

Clinical Staging After Diagnosis

Once ABPA is confirmed, staging helps guide treatment intensity and set expectations. The classic staging system, proposed after following 40 patients over several years, defines five stages:²²

Acute: All diagnostic criteria are active and the patient responds to corticosteroids.
Remission: Stable, without significant asthma flares or new infiltrates.
Exacerbation: Recurrent flares of active ABPA after a period of remission.
Steroid-dependent asthma: Asthma that requires continuous corticosteroids, with or without ABPA exacerbations.
Fibrotic: Irreversible lung scarring with a worse prognosis.

These stages are not strictly sequential. Some patients bounce between remission and exacerbation for years, while others progress to the fibrotic stage despite treatment. The staging system is most useful as a communication tool among clinicians and a framework for deciding when to escalate therapy.

When the Fungus Is Not Aspergillus

Although A. fumigatus causes the vast majority of cases, other fungi can trigger an identical syndrome, broadly termed allergic bronchopulmonary mycosis (ABPM). Organisms including Curvularia, Candida, Schizophyllum, and others have been reported. The diagnostic challenge with non-Aspergillus ABPM is considerable: there are no validated serological tests for many of these fungi, skin testing antigens are not routinely available, and the ABPA diagnostic criteria were never formally validated for other species.²³ Clinicians diagnosing non-fumigatus ABPM typically have to extrapolate from the ABPA literature, relying on the overall clinical pattern (elevated IgE, bronchiectasis, eosinophilia, positive culture for the implicated fungus) while acknowledging that the diagnostic certainty is lower.

Point-of-Care Testing in Resource-Limited Settings

Standard ABPA workup requires a laboratory capable of running multiple serological tests, which is not always available in lower-resource settings. Lateral flow immunochromatographic (ICT) assays, similar in concept to rapid COVID or pregnancy tests, have been explored as a way to screen for Aspergillus sensitization at the bedside. Early results suggest these rapid assays could be useful for ruling out ABPA: a negative test in someone with moderate to severe asthma makes ABPA unlikely and could spare the patient a lengthy serological workup. However, positive results still need confirmation through standard blood tests.²⁴ The evidence base is still small, and these assays are not yet part of any major diagnostic guideline.

ABPA in Children

Pediatric ABPA exists but is reported less frequently than in adults, which may partly reflect underrecognition. Children present with the same constellation of poorly controlled asthma, elevated eosinophils, high IgE, and Aspergillus-specific IgE. Case reports emphasize the importance of considering ABPA in any child whose asthma does not respond as expected to standard therapy, particularly when eosinophilia and very high IgE levels are present. Misdiagnosis as a simple asthma exacerbation or recurrent infection is common, and clinicians may need to actively pursue the serological workup rather than waiting for the diagnosis to declare itself radiologically.

Environmental Exposure and Its Place in the Diagnostic Picture

ABPA is fundamentally an immunological overreaction, not a simple infection, so environmental fungal exposure is not typically part of the diagnostic criteria. Still, the amount of Aspergillus a person is exposed to at home could influence disease risk and flare frequency. A small study of cystic fibrosis patients found significantly higher concentrations of A. fumigatus DNA in the homes of ABPA patients compared to those without the disease, using specialized dust-sampling methods. While this does not translate into a diagnostic test, it raises the possibility that reducing household mold exposure could be a meaningful adjunct for people at high risk of ABPA, a question that remains largely unstudied in controlled trials.